Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy

被引：10

作者：

Kim, Jong Taek ^{[1
]}

Zhang, Wenjuan ^{[1
]}

Lopategui, Jean ^{[1
,2
]}

Vail, Eric ^{[1
,2
]}

Balmanoukian, Ani ^{[2
,3
]}

机构：

[1] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA

[2] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA

[3] Angeles Clin & Res Inst, Los Angeles, CA USA

来源：

JCO PRECISION ONCOLOGY | 2021年 / 5卷

关键词：

LUNG-CANCER; BRAIN METASTASES; KDD;

D O I：

10.1200/PO.20.00296

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：88 / 92

页数：5

共 20 条

[1] Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication [J].

Baik, Christina S. ;

Wu, David ;

Smith, Christina ;

Martins, Renato G. ;

Pritchard, Colin C. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (10) :E97-E99

[2] Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity [J].

Ballard, Peter ;

Yates, James W. T. ;

Yang, Zhenfan ;

Kim, Dong-Wan ;

Yang, James Chih-Hsin ;

Cantarini, Mireille ;

Pickup, Kathryn ;

Jordan, Angela ;

Hickey, Mike ;

Grist, Matthew ;

Box, Matthew ;

Johnstrom, Peter ;

Varnas, Katarina ;

Malmquist, Jonas ;

Thress, Kenneth S. ;

Janne, Pasi A. ;

Cross, Darren .

CLINICAL CANCER RESEARCH, 2016, 22 (20) :5130-5140

[3] Improving outcomes for brain metastases in EGFR mutated NSCLC [J].

Carlisle, Jennifer W. ;

Ramalingam, Suresh S. .

TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 :S355-S359

[4] A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring anEGFR-KDD and Response to Afatinib [J].

Chen, Dong ;

Li, Xing-liang ;

Wu, Biao ;

Zheng, Xiao-bin ;

Wang, Wen-xian ;

Chen, Hua-fei ;

Dong, Yi-yu ;

Xu, Chun-wei ;

Fang, Mei-yu .

FRONTIERS IN ONCOLOGY, 2020, 10

[5]

Ettinger D.S., 2020, Continue NCCN Guidelines Panel Disclosures NCCN Guidelines Version 3.2020 Non-Small Cell Lung Cancer

[6]

FDA, 2020, Highlights of prescribing information

[7] EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib [J].

Gallant, Jean-Nicolas ;

Sheehan, Jonathan H. ;

Shaver, Timothy M. ;

Bailey, Mark ;

Lipson, Doron ;

Chandramohan, Raghu ;

Brewer, Monica Red ;

York, Sally J. ;

Kris, Mark G. ;

Pietenpol, Jennifer A. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Ali, Siraj M. ;

Meiler, Jens ;

Lovly, Christine M. .

CANCER DISCOVERY, 2015, 5 (11) :1155-1163

[8] CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials [J].

Goss, G. ;

Tsai, C-M ;

Shepherd, F. A. ;

Ahn, M-J ;

Bazhenova, L. ;

Crino, L. ;

de Marinis, F. ;

Felip, E. ;

Morabito, A. ;

Hodge, R. ;

Cantarini, M. ;

Johnson, M. ;

Mitsudomi, T. ;

Janne, P. A. ;

Yang, J. C-H .

ANNALS OF ONCOLOGY, 2018, 29 (03) :687-693

[9] Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer [J].

Liam, Chong-Kin .

ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (03)

[10] Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity [J].

Marcar, Lynnette ;

Bardhan, Kankana ;

Gheorghiu, Liliana ;

Dinkelborg, Patrick ;

Pfaffle, Heike ;

Liu, Qi ;

Wang, Meng ;

Piotrowska, Zofia ;

Sequist, Lecia V. ;

Borgmann, Kerstin ;

Settleman, Jeffrey E. ;

Engelman, Jeffrey A. ;

Hata, Aaron N. ;

Willers, Henning .

CELL REPORTS, 2019, 27 (12) :3422-+

← 1 2 →